Search
Fesoterodine
go.drugbank.com/drugs/DB06702ApprovedFesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Mirtazapine
go.drugbank.com/drugs/DB00370ApprovedInvestigationalIt may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.[A177811]
Dorocubicel
go.drugbank.com/drugs/DB19448Approved[L54146] It is one component of a cell therapy, Zemcelpro, that also contains [unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells].
Fenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigationalIt works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.
Dihydroergocristine
go.drugbank.com/drugs/DB13345Approved[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.
Sulfacytine
go.drugbank.com/drugs/DB01298ApprovedIt inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase.
Butyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl. … [A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.
Ethoheptazine
go.drugbank.com/drugs/DB08988ApprovedWithdrawnIt is a phenazepine based opioid analgesic. It was invented in the 1950s and is related to other drugs such as proheptazine. Ethoheptazine is no longer marketed in the United States.
Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedIt aims to reduce the duration of neutropenia and the incidence of febrile neutropenia. … It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia.
Zileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnSpecifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems.